all report title image

HEREDITARY DEAFNESS MARKET ANALYSIS

Hereditary Deafness Market, by Product Type (Hearing Aids (Behind-The-Ear Hearing Aids and In-The-Ear Hearing Aids), Hearing Implants (Cochlear Implants, Bone Conduction Devices, Middle Ear Implants, and Brain Stem Implants), and Other Assistive Devices), by End User (Hospitals, Clinics, Otolaryngologists, Ambulatory Surgical Centers, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2022-2028

  • To Be Published : Dec 2024
  • Code : CMI4854
  • Formats :
      Excel and PDF
  • Industry : Medical Devices

Hereditary Deafness MarketSize and Trends

Global Hereditary Deafness Market– Dynamics

The rising prevalence of hearing loss across the globe is expected to propel the global hereditary deafness market growth. For instance, on April 01, 2021, according to the data published by the World Health Organization (WHO), it is expected that by 2050, around 2.5 billion people of global population will have some extent of hearing loss and at least 700 million will need hearing rehabilitation.

Recent product launches and approvals is expected to boost the global hereditary deafness market growth. For instance, on March 18, 2020, Cochlear Medical Device Company India Pvt Ltd, received the U.S. Food and Drug Administration approval for Cochlear nucleus implantsto lower the age criteria for cochlear implantation from 12 months to 9 months for children having congenital deafness.

Moreover, on June 17, 2019, Cochlear Medical Device Company India Pvt Ltd, received the U.S.FDA clearance for the Cochlear Osia 2 System, which is a new category of bone conduction hearing solutions.

Similarly, on June 29, 2020, the U.S. Food and Drug Administration acknowledged the Breakthrough Device Designation to Envoy Medical Corporation’s, Acclaim cochlear implant.

Furthermore, on August 26, 2020, MED-EL’s new lightweight and slim RONDO 3 audio processor received U.S. FDA approval for the SYNCHRONY Cochlear Implant System.

In addition, rising ongoing clinical trials of drugs is expected to augment the hereditary deafness market growth. For instance, on July 23, 2020, Pipeline Therapeutics, a biopharmaceutical company announced the initiation of Phase 1/2a trial of a gamma secretase inhibitor, PIPE-505, in sensorineural hearing loss. These factors are expected to drive the global hereditary deafness market growth over the forecast period.

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

Customize Now
Logo

Credibility and Certifications

ESOMAR
DUNS Registered
Clutch
DMCA Protected

9001:2015

Credibility and Certifications

27001:2022

Credibility and Certifications

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo
© 2024 Coherent Market Insights Pvt Ltd. All Rights Reserved.